Olanzapine Apotex

On 12 August 2025, the European Commission withdrew the marketing authorisation for Olanzapine Apotex (olanzapine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Apotex Europe B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Olanzapine Apotex was granted marketing authorisation in the EU on 10 June 2010 for the treatment of schizophrenia and moderate to severe manic episode. The marketing authorisation was initially valid for a 5\-year period. It was then granted unlimited validity in 2014\. Olanzapine Apotex is a generic medicine of Zyprexa. There are other generic medicinal products of Zyprexa authorised and marketed in the EU.